Use of Salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases

US9630999B2 · kind B2 · utility

Assignees

• Suzhou Sciscape Biomedicine Science & Technology Co. Ltd. · CN
• Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China · CN

Inventors

• Chenggang Zhang · 安丰镇, CN
• Junhuai Li · 林湖乡, CN
• Yang Xu · Wenhe, CN
• Yonghong Wu · Beijing, CN
• Weiguang Li · Shanghai, CN
• Yanchun Zhang · Beijing, CN
• Yan Gao · Boca Raton, US
• Zhihui Li · Hangzhou City, CN

Key dates

• Filing date: Nov 13, 2015
• Grant date: Apr 25, 2017
• Expiry date: Nov 13, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.